Insulet Corporation, a global leader in tubeless insulin pump technology with its Omnipod brand, has received FDA 510(k) clearance for major updates to the Omnipod 5 Automated Insulin Delivery System.
The new algorithm features a lower 100 mg/dL Target Glucose and smoother automated insulin delivery, designed to simplify daily use while improving clinical outcomes.
Health Technology Insights: University of Rochester Medical Center and GE HealthCare Launch 7-Year Care Alliance
Eric Benjamin, Executive Vice President and Chief Operating Officer at Insulet, said, “This is the most substantial algorithm upgrade since the Omnipod 5 launch in 2022. These enhancements reflect our commitment to meaningful innovation, providing a system that is more personalized, simpler to use, and supports better glucose management.”
Health Technology Insights: AI Governance in Drug Safety: Lessons from IQVIA
The new 100 mg/dL target expands customization to six settings between 100 and 150 mg/dL in 10 mg/dL increments, enabling healthcare providers to fine-tune therapy and support tighter glucose control.
The updated algorithm also helps users stay in Automated Mode with fewer interruptions, even during prolonged high glucose events, offering more consistent insulin delivery and improved time in range. Dr. Anita Swamy, MD, Pediatric Endocrinologist and Medical Director of the Chicago Children’s Diabetes Center, added, “These updates are an important step forward. More target options and fewer interruptions allow patients to manage diabetes with greater confidence while maintaining strong clinical outcomes.” These enhancements highlight Insulet’s focus on patient-centric design and continuous innovation to improve the daily experience for people with diabetes and the healthcare providers who support them.
Health Technology Insights: GE HealthCare Launches Imaging 360 Powered By AI to Improve Operations Efficiency
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
